ada standards of care 2025 obesity pharmacotherapy glp-1 recommendations 🆕 guideline release American Diabetes Association Pharmacologic Treatment Obesity in Adults: of in Overweight and Obesity adds to the list of guidelines published this past year summarizing Frontiers | Pharmacotherapy for obesity:

The biological impact of GLP-1RAs on cancer risk operates through multiple mechanistic pathways, including direct effects on tumor cell metabolism and proliferation, modulation of immune responses in the tumor microenvironment, and regulation of inflammatory signaling networks (911)

Dose escalation is when gastrointestinal side effects peak, creating the highest risk of dehydration and associated UTI vulnerability

Sawami K, Tanaka A, Node K (2022) Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists

*Based on a 2024 survey of pharmacists who recommend branded vitamins and supplements

The team is personable, engaged, and quietly confident

[10] Engeroff, T., Groneberg, D.A